Last updated on January 2019

A Study of the Safety and Pharmacokinetics of Apixaban Versus Vitamin K Antagonist (VKA) or Low Molecular Weight Heparin (LMWH) in Pediatric Subjects With Congenital or Acquired Heart Disease Requiring Anticoagulation


Brief description of study

To investigate the safety and pharmacokinetics of apixaban in children with congenital or acquired heart disease who have a need for anticoagulation.

Clinical Study Identifier: NCT02981472

Find a site near you

Start Over

Local Institution

Helsinki, Finland
6.93miles
  Connect »